UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/750,079	12/31/2003	Sepehr Fariabi	ACSG-66757 (0970CCC)	1878
24201 FULWIDER PA	7590 04/17/200 ATTON LLP	EXAMINER		
	GHES CENTER	PREBILIC, PAUL B		
	NTER DRIVE, TENTH FLOOR GELES, CA 90045		ART UNIT	PAPER NUMBER
			MAIL DATE	DELIVERY MODE
			04/17/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/750,079	FARIABI, SEPEHR		
Office Action Summary	Examiner	Art Unit		
	Paul B. Prebilic	3774		
The MAILING DATE of this communication a Period for Reply	ppears on the cover sheet with	the correspondence address		
A SHORTENED STATUTORY PERIOD FOR REP WHICHEVER IS LONGER, FROM THE MAILING  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period.  - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the main earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNICA 1.136(a). In no event, however, may a repl od will apply and will expire SIX (6) MONTH ute, cause the application to become ABAN	TION.  y be timely filed  S from the mailing date of this communication.  DONED (35 U.S.C. § 133).		
Status				
1) ☐ Responsive to communication(s) filed on <u>07</u> 2a) ☐ This action is <b>FINAL</b> . 2b) ☐ The solution of the condition of the c	nis action is non-final. vance except for formal matter			
Disposition of Claims				
4) ☐ Claim(s) 37-85 is/are pending in the applicat 4a) Of the above claim(s) is/are withdi 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 37-85 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and  Application Papers	rawn from consideration.  I/or election requirement.			
9) The specification is objected to by the Examination The drawing(s) filed on is/are: a) and a specificant may not request that any objection to the Replacement drawing sheet(s) including the correct to be a specific to by the specific to by the specific to be specifically and specifically ano	ccepted or b) objected to by ne drawing(s) be held in abeyance ection is required if the drawing(s)	. See 37 CFR 1.85(a). is objected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/N	nmary (PTO-413) /lail Date rmal Patent Application		

## Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 7, 2008 has been entered.

### Terminal Disclaimer

The terminal disclaimer filed on January 7, 2008 disclaiming the terminal portion of any patent granted on this application which would extend beyond the expiration date of US Patents 6827734, 6419693, and 5636641 have been reviewed and is accepted. The terminal disclaimer has been recorded.

## Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 37-85 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The new element made of tungsten, iron or

Art Unit: 3774

manganese lacks original support. An RCE cannot be used as a means to add additional subject matter; see 37 CFR 1.114.

The Applicant cited page 3, lines 19-20 for support of the subject matter added to the claims. However, this passage only states that "other alloying components include up to about 20% tungsten, up to about 20% iron, and up to about 3% manganese." In other words, an elongate member is made of an alloy that can contain 4 metals along with up to three optional metals of tungsten, iron, and manganese. There is no suggestion that different elements can have different compositions as the claims now suggest. The Examiner suggests changing the language "and one metallic element" to --- and one alloy component selected--- in order to overcome this rejection.

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 37-50, 53, 54, 56-76, and 78-85 are rejected under 35 U.S.C. 103(a) as being unpatentable over Robinson et al (US 5,891,193) in view of Mayer (US 5,824,077). Robinson meets the claim language where the stent of Robinson has a relaxed state where it will not self expand, but it is capable of being bent (permanently deformed) to form the stent; see column 5, lines 31-51. Therefore, the stent is plastically deformable and could be expanded to a state where there would be no bends in the wires; this unbent expanded diameter reads on the "diameter suitable to hold"

open the coronary artery" as claimed. Particularly, the size of a coronary vessel varies depending upon the particular patient being treated, and thus, the size of the device as claimed is met by Robinson's device which is also balloon expandable to an unbent form of the segments (33). The unbent form and the other forms thereof are the size of some individuals. Additionally, self-expansion depends upon how the device is used and how it is biased. For this reason, the Examiner maintains that the claim language is read on by Robinson's device as it is disclosed.

The claimed alloy of the claimed stent is extremely similar to the material (MP35N from Carpenter Technology) of Robinson's device; see Robinson on column 5, lines 34-38 and see the present specification on page 13. However, Robinson fails to disclose an alloy containing iron, tungsten, or manganese as claimed.

Mayer teaches that MP35N was known to be closely related and interchangeable with ELGILOY that does contain iron; see column 3, line 60 to column 4, line 3. Therefore, it is the Examiner's position that it would have been clearly obvious to an ordinary artisan to utilize ELGILOY as the alloy of Robinson for the reason it was chosen over MP35N by Mayer. Alternatively, it would have been obvious to encase the MP35N stent of Robinson with ELGILOY in order to improve the mechanical properties or for the same reasons that Mayer chose ELGILOY over MP35N as the casing material; see the abstract of Mayer

With regard to the new limitations of claim 37, due to the fact that permanent bends can be put in the wires of Robinson, the Examiner asserts that there is inherently a state of compression that would plastically deform the stent of Robinson since the low

Art Unit: 3774

profile configuration has no limit and includes placing a plastically deforming amount of pressure on the stent to compress it.

With regard to claim 50, Robinson fails to disclose the percentage of nickel claimed. However, at the time the invention was made, it would have been an obvious matter of design choice to a person of ordinary skill in the art to utilize a 2% nickel alloy because Applicants have not disclosed that doing so provides some advantage, is used for a particular purpose, or solves a stated problem. One of ordinary skill in the art, furthermore, would have expected Applicants' invention to perform equally well as a stent. Therefore, it would have been an obvious matter of design choice to modify Robinson to obtain the invention as specified in the claims.

With regard to claim 59, Applicants are directed to Figure 2 of Robinson.

With regard to claims 60 and 61, the aspect ratio claimed is considered be to be broad because it is associated with the modifier "about." For this reason and upon inspection of Robinson's figures, the Examiner determined that the claimed aspect ratios claimed are met by Robinson; see Figure 2, which is read on by the present claim language for claim 60 and see Figure 4 for the ratio of two to one.

With regard to claims 54, 62-71, and 75, the electrochemical polishing step is considered to be a product-by-process limitation. Since the degree that this step is performed is not specified, the Examiner posits that it would not result in a product that is different that that disclosed by Robinson; see MPEP 2113, which is incorporated herein by reference. Alternatively, the Examiner asserts that the claimed invention, if

different, is only slightly different. For this reason, the claim language is considered to be at least clearly obvious in view of Robinson alone.

With regard to claims 70 and 71, the aspect ratio claimed is considered be to be broad because it is associated with the modifier "about." For this reason and upon inspection of Robinson's figures, the Examiner determined that the aspect ratios claimed are met by Robinson.

With regard to claims 68, 69, and 76, the cold working or age hardening step is considered to be a product-by-process limitation. Since the degree that this step is performed is not specified, the Examiner posits that it would not result in a product that is different that that disclosed by Robinson; see MPEP 2113, which is incorporated herein by reference. Alternatively, the Examiner asserts that the claimed invention, if different, is only slightly different. For this reason, the claim language is considered to be at least clearly obvious in view of Robinson alone.

With regard to claims 84 and 85, the step of cutting voids from a member is considered to be a product-by-process limitation. Since Robinson also discloses a stent with voids therein, the Examiner posits that process of cutting would not result in a product that is different that that disclosed by Robinson; see MPEP 2113, which is incorporated herein by reference. Alternatively, the Examiner asserts that the claimed invention, if different, is only slightly different. For this reason, the claim language is considered to be at least clearly obvious in view of Robinson alone.

Application/Control Number: 10/750,079 Page 7

Art Unit: 3774

Claims 51 and 52 are rejected under 35 U.S.C. 103 as being unpatentable over Robinson et al (US 5,891,193) and Mayer (US 5,824,077) as applied against claim 37 above, and further in view of Hillstead (US 4,856,516) or Tower (US 5,217,483). Robinson et al as modified by Mayer meets the claim language except for the transverse diameter of about 0.003 inches. However, Hillstead (see column 3, lines 43-45) and Tower (see column 2, lines 34-43) both disclose stents constructed of wires having a diameter (which would be the transverse diameter) of about 0.003 inches. Hence, it is the Examiner's position that it would have been obvious to construct the Robinson device with wires of about 0.003 inches for the same reasons that Hillstead and Tower do the same and in order have a low profile for the stent.

Claims 55 and 77 are rejected under 35 U.S.C. 103(a) as being unpatentable over Robinson et al (US 5,891,193) and Mayer (US 5,824,077) as applied against claim 37 above, and further in view of Bokros (US 4,300,244). Robinson fails to disclose the use of a biocompatible coating thereon. However, Bokros teaches that it was known to coat similar cardiovascular implants with biocompatible coating in order to render them more biocompatible; see column 2, lines 16-24. Therefore, it is the Examiner's position that it would have been obvious to coat the Robinson device with a biocompatible coating to make it more biocompatible.

## Response to Arguments

Applicant's arguments with respect to the claims have been considered but are moot in view of the new ground(s) of rejection.

#### Conclusion

Art Unit: 3774

Applicant should specifically point out the support for any amendments made to the disclosure, including the claims (MPEP 714.02 and 2163.06). Due to the procedure outlined in MPEP 2163.06 for interpreting claims, it is noted that other art may be applicable under 35 USC 102 of 35 USC 103(a) once the aforementioned issue(s) is/are addressed.

Applicant is respectfully requested to provide a list of all copending applications that set forth similar subject matter to the present claims. A copy of such copending claims is respectfully requested in response to this Office action if the application is not stored in image format (i.e. the IFW system) or published.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Paul B. Prebilic whose telephone number is (571) 272-4758. He can normally be reached on 6:30-5:00 M-Th.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on 571-272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Paul Prebilic/ Paul Prebilic Primary Examiner Art Unit 3774